• In Memory of Timothy Ray Brown

    October 2, 2020 Alexis Sexton Spotlight

    With great sorrow, we share the news that Timothy Ray Brown passed on September 29, 2020. Timothy, who was previously known as the “Berlin Patient,” was the first person cured of HIV when he received bone marrow and stem cell transplants to treat his leukemia. The return of that cancer caused his death. To read more about Timothy please click here. To read the NY Times article on him click here.

  • ACTG REPRIEVE Chosen for ViiV Grant

    Congratulations to ACTG REPRIEVE, study A5332, for receiving a ViiV Global HIV and COVID-19 Emergency Response Fund grant! ViiV included REPRIEVE as one of 109 grantees out of over 400 grant applications.

  • An Update on A5395

    ACTG recently announced that it has stopped enrolling A5395, our clinical trial evaluating whether hydroxychloroquine and azithromycin can prevent hospitalization and death from COVID-19. This action was taken when it was determined that the rate of participant enrollment was insufficient for the trial to meet its objectives in a timely manner. No safety concerns were associated with the trial. ACTG remains highly involved in efforts to address COVID-19, having been asked to lead a Master Adaptive protocol under the Accelerating COVID-19 Therapeutic Interventions and Vaccine (ACTIV) Operation Warp Speed. This trial (ACTG 5401 or ACTIV-2) will evaluate multiple monoclonal antibodies and other small molecules for outpatient COVID treatment. The trial is set to open at the end of July.”

  • A Message from Leadership

    The ACTG leadership has watched with sadness and horror the recent racially motivated violent events, including the deaths of George Floyd by the police in Minneapolis, Ahmaud Arbery when out for a jog in South Georgia, and Breonna Taylor in her own home by police in Louisville, Kentucky. These devastating events are taking place in the context of the COVID-19 pandemic and subsequent economic downfall, both of which have disproportionately affected racial/ethnic minorities in the United States. The ACTG mourns these brutal deaths and recognizes the structural racism in the United States that has paved the way for these unjust murders and facilitated the disproportionate impact of COVID-19 on black and brown communities. We understand and empathize with the anger and frustration that is being felt and expressed across our nation about these senseless deaths and the injustice they represent. The ACTG and the HIV/AIDS community are committed to social justice and eliminating these disparities. Now is the time for us to all stand together and do our part to support efforts to dismantle structural racism, injustice, and brutality in the United States.

  • Larry Kramer

    The ACTG is deeply saddened by the passing of AIDS activist and playwright, Larry Kramer. To read more about his life and legacy, please see the New York Times article here.

  • Long-acting injectable cabotegravir is highly effective for the prevention of HIV infection in cisgender men and transgender women who have sex with men

    The HIV Prevention Trials Network (HPTN) announced today results from HPTN 083, a global randomized, controlled, double-blind study that compared the safety and efficacy of long-acting injectable cabotegravir (CAB LA) to daily oral tenofovir/emtricitabine (TDF/FTC) (Truvada) for pre-exposure prophylaxis (PrEP). The study showed that CAB LA lowered HIV incidence among cisgender men and transgender women who have sex with men. During a planned review of study data, an independent Data and Safety Monitoring Board (DSMB) recommended that the study results be announced as soon as possible. The study sponsor, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, agreed with this recommendation.

    A companion study, HPTN 084, is comparing the efficacy and safety of CAB LA to daily oral TDF/FTC for PrEP among women in sub-Saharan Africa. This study, which began approximately a year after HPTN 083, was also reviewed by the DSMB and was recommended to continue as planned.

     

    This information was provided by HPTN. To read more about this please click here.

  • Gita Ramjee

    We are writing to share the sad news about the passing of one of our very dearest colleagues, Gita Ramjee. The cause of death is from complications of COVID-19. Words cannot express the sorrow we feel. Gita was a tremendous force within the field and was part of the MTN family from day one. As you all know she directed the MRC CTU in Durban for many years, and in May 2019 refocused her efforts toward spending more time with her sons living in London and enjoying her grandson who is about 6 months old. Gita had a tremendous passion for HIV prevention and she cared deeply about addressing the disparities in HIV incidence in young women. It wasn’t too long ago that she wrote in an email, “It has been a long road with many ups and downs but we have forged along with strong determination.” She was always impeccably dressed. She always had a beautiful manicure. She always had a big smile. We will always appreciate her role in the MTN family.

    We will miss Gita and wish her family comfort during this time of unfathomable loss.

     

    This information was provided by MTN.

  • 2019 Year In Review

    December 27, 2019 Alexis Sexton Spotlight

    A note from Dr. Currier and Dr. Eron about the past year.

    Goodbye 2019!